BlossomHill Therapeutics (NASDAQ:BLSM) Announces Quarterly Earnings Results

BlossomHill Therapeutics (NASDAQ:BLSM) issued its earnings results on Friday. The company reported ($8.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($7.91), Zacks reports.

BlossomHill Therapeutics Stock Performance

NASDAQ BLSM opened at $25.74 on Friday. BlossomHill Therapeutics has a 52 week low of $15.25 and a 52 week high of $27.80.

Analyst Ratings Changes

Several research analysts recently commented on BLSM shares. Leerink Partners began coverage on shares of BlossomHill Therapeutics in a research note on Tuesday, September 1st. They issued an “outperform” rating and a $36.00 price target on the stock. Lifesci Capital began coverage on shares of BlossomHill Therapeutics in a research note on Tuesday, September 1st. They issued an “outperform” rating and a $32.00 price objective for the company. JPMorgan Chase & Co. began coverage on BlossomHill Therapeutics in a research report on Tuesday, September 1st. They set an “overweight” rating and a $28.00 target price on the stock. Guggenheim began coverage on shares of BlossomHill Therapeutics in a research report on Tuesday, September 1st. They issued a “buy” rating and a $30.00 price objective for the company. Finally, Wall Street Zen upgraded shares of BlossomHill Therapeutics to a “hold” rating in a research note on Saturday, August 15th. Five equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $32.20.

Insider Activity

In related news, Director John P. Schmid acquired 6,000 shares of BlossomHill Therapeutics stock in a transaction that occurred on Monday, August 10th. The shares were purchased at an average cost of $16.00 per share, for a total transaction of $96,000.00. Following the acquisition, the director owned 6,000 shares in the company, valued at approximately $96,000. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, General Counsel Vincent Liptak purchased 2,200 shares of BlossomHill Therapeutics stock in a transaction dated Monday, August 10th. The stock was bought at an average cost of $16.00 per share, for a total transaction of $35,200.00. Following the completion of the purchase, the general counsel directly owned 111,412 shares in the company, valued at approximately $1,782,592. This trade represents a 2.01% increase in their position. The SEC filing for this purchase provides additional information. In the last quarter, insiders have bought 1,573,900 shares of company stock worth $25,181,900.

About BlossomHill Therapeutics

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.